Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of almond, dark chocolate, and cocoa consumption with stool microbial diversity and composition among adults with overweight or obesity: An analysis of secondary outcomes from a 4-period crossover clinical trial.

Clinical nutrition ESPEN·2026
Same author

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series.

Cancer reports (Hoboken, N.J.)·2026
Same author

We Thought You'd Never Ask: Insights From the Health of Elite Retired Australian Female Athletes Survey.

Journal of sport rehabilitation·2026
Same author

Cocooning Nurse Autonomy in Türkiye: Navigating a Path to Professionalism That Does Not Challenge Medical Dominance.

Sociology of health & illness·2026
Same author

Antibody responses to inactivated (adjuvanted) and attenuated (non-adjuvanted) feline panleukopaenia virus vaccination, including in different injection sites.

Journal of feline medicine and surgery·2026
Same author

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study.

BMJ open·2026

Related Experiment Video

Updated: Jun 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Angiosarcoma.

Robin J Young1, Nicola J Brown, Malcolm W Reed

  • 1Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK. r.j.young@shefeld.ac.uk

The Lancet. Oncology
|June 12, 2010
PubMed
Summary
This summary is machine-generated.

Angiosarcomas, rare endothelial cancers, have a poor prognosis. Current research focuses on vascular-targeted drugs and clinical trials for advanced angiosarcoma treatment.

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

  • Oncology
  • Pathology
  • Vascular Biology

Background:

  • Angiosarcomas are rare soft-tissue sarcomas originating from endothelial cells.
  • They commonly affect the skin, particularly the head and neck in elderly men.
  • Secondary angiosarcomas, especially in the breast, arise from therapeutic radiation or chronic lymphoedema.

Purpose of the Study:

  • To review the current understanding of angiosarcoma biology.
  • To discuss the management strategies for angiosarcoma.
  • To highlight ongoing clinical trials for advanced angiosarcoma treatment.

Main Methods:

  • Literature review of angiosarcoma pathogenesis and treatment.
  • Analysis of current clinical trial data for vascular-targeted therapies.
  • Discussion of management based on disease presentation and risk factors.

Main Results:

  • Angiosarcomas exhibit poor prognosis with limited treatment options.
  • Vascular-targeted therapies are emerging as a promising treatment avenue.
  • Understanding molecular biology aids in identifying specific treatment targets.

Conclusions:

  • Angiosarcoma management requires a multidisciplinary approach.
  • Clinical trials investigating novel therapies are crucial for improving outcomes.
  • Targeted therapies show potential for controlling advanced angiosarcoma.